Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1152 · 5 trials · 3 indications
Percentage of patients achieving either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi). Per Cheson Criteria: Confirmed complete remission (CRi) is defined as a disappearance of blasts in the peripheral blood; a decrease in bone marrow blasts to \<5% total bone marrow nucleated cells demonstrated in bone marrow aspirate; absence of Auer rods; no persistent extramedullary leukaemia. Complete response (CR) is defined as all requirements to meet CRi and in addition: recovery of neutrophils to ≥1.0 x 109/L and platelets to ≥100 x 109/L; transfusion-independence.
| Arm | Type | Description |
|---|---|---|
| AZD1152 1200 mg | EXPERIMENTAL | AZD1152 1200 mg, iv, 7 day infusion monotherapy |
| LDAC 20 mg | ACTIVE_COMPARATOR | LDAC 20 mg, sc, bd, 10 days (400mg per cycle) |
| AZD1152 | EXPERIMENTAL | 100 mg Lyophile 5 mL Diluent |
| C14 AZD1152 | EXPERIMENTAL | AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial. |
| 1 | EXPERIMENTAL | AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.) |
| Name | Type | Description |
|---|---|---|
| AZD1152 | DRUG | 1200 mg, iv, 7 day infusion |
| LDAC | DRUG | 20 mg, sc, bd, 10 days |
| C14 AZD1152 | DRUG | radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion |
| LDAC (low dose cytosine arabinoside) | DRUG | 20 mg subcutaneous injection given twice daily |
Inclusion Criteria: * Provision of written informed consent * Newly diagnosed male or female patients aged 60 and over * De Novo or Secondary AML * Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following:Age ≥75 years; Adve...
AZD1152 is an investigational small molecule being studied for the treatment of acute myeloid leukemia (AML), also referred to as acute myeloid leukaemia. It is being developed by AstraZeneca PLC (ticker: AZN) and is currently in Phase 1 clinical development for this hematologic malignancy.
AZD1152 is a small molecule being developed by AstraZeneca PLC for acute myeloid leukemia. While its specific molecular target has not been disclosed in the available information, it is being investigated as a potential treatment for this blood cancer.
AZD1152 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical trials for the treatment of acute myeloid leukemia.
AZD1152 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with acute myeloid leukemia.
AZD1152 has been studied in several completed clinical trials, including NCT00530699, a Phase 1 study in patients with relapsed acute myeloid leukemia in Japan, and NCT00926731, a Phase 1 study combining AZD1152 with low dose cytosine arabinoside in the United States and France.
AZD1152 is also known as barasertib, a prodrug of the Aurora B kinase inhibitor barasertib-hQPA. It is being developed by AstraZeneca PLC for the treatment of acute myeloid leukemia and is currently in Phase 1 clinical trials.